Replies to post #183548 on Biotech Values

[DewDiligence]

OHRP—I missed this PR from mid-2014:

http://ir.ohrpharmaceutical.com/press-releases/detail/194/depymed-announces-validation-of-trodusquemine-as-a-therapeutic-candidate-for-her2-positive-breast-cancer

Hard to believe that Cold Spring Laboratory is interested in Trodusquemine, the former “obesity” drug from Genaera, as a cancer treatment.

[DewDiligence]

OHRP sells 4.26M* shares @$6.75—a 12% discount to yesterday’s close:

http://finance.yahoo.com/news/ohr-pharmaceutical-prices-25-000-133000418.html

*Assuming exercise of underwriter’s option.